SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ: SLS · Real-Time Price · USD
1.215
-0.025 (-2.02%)
Nov 21, 2024, 12:23 PM EST - Market open
SLS Employees
SELLAS Life Sciences Group had 16 employees as of December 31, 2023. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
n/a
Profits / Employee
-$2,017,500
Market Cap
78.16M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
EDAP TMS | 307 |
Adicet Bio | 143 |
Allakos | 131 |
LENSAR | 130 |
Scilex Holding Company | 105 |
HilleVax | 90 |
Genelux | 23 |
Regencell Bioscience Holdings | 12 |
SLS News
- 7 days ago - SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 days ago - voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS) - Business Wire
- 16 days ago - SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024 - GlobeNewsWire
- 5 weeks ago - SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia - GlobeNewsWire
- 5 weeks ago - SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 3 months ago - SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas - GlobeNewsWire
- 4 months ago - SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia - GlobeNewsWire